These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 2498563)
1. [A case of thymoma associated with prostatic cancer]. Isurugi K; Kondo Y; Oyamatsu T; Hirasawa K; Honma Y; Masuda S; Yoshino S; Yakumaru K Nihon Hinyokika Gakkai Zasshi; 1989 Jan; 80(1):100-3. PubMed ID: 2498563 [TBL] [Abstract][Full Text] [Related]
2. [Treatment of prostatic cancer with slow-release formulation of luteinizing hormone releasing hormone (LH-RH) analog]. Fuse H; Akimoto S; Akakura K; Shimazaki J; Murakami S Hinyokika Kiyo; 1988 Mar; 34(3):555-60. PubMed ID: 3133936 [TBL] [Abstract][Full Text] [Related]
3. [Clinical and endocrinological studies of the luteinizing hormone-releasing hormone analogue therapy in prostatic cancer patients]. Nagai A; Ohashi T; Irie S; Ohashi Y; Yamashita Y; Matsumura Y; Ohmori H; Tanahashi T; Nanba K Nihon Hinyokika Gakkai Zasshi; 1989 Jun; 80(6):891-8. PubMed ID: 2529389 [TBL] [Abstract][Full Text] [Related]
4. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice. Redding TW; Schally AV; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs JT Cancer Res; 1992 May; 52(9):2538-44. PubMed ID: 1568223 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of prostate. Santen RJ; Warner B Urology; 1985 Feb; 25(2 Suppl):53-7. PubMed ID: 3918377 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75. Korkut E; Bokser L; Comaru-Schally AM; Groot K; Schally AV Proc Natl Acad Sci U S A; 1991 Feb; 88(3):844-8. PubMed ID: 1992476 [TBL] [Abstract][Full Text] [Related]
7. Interim report of a large French multicentre study of efficacy and safety of 3.75 mg leuprorelin depot in metastatic prostatic cancer. Giraud B J Int Med Res; 1990; 18 Suppl 1():84-9. PubMed ID: 1691113 [TBL] [Abstract][Full Text] [Related]
8. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer. Pinski J; Halmos G; Szepeshazi K; Schally AV Cancer; 1993 Dec; 72(11):3263-70. PubMed ID: 8242552 [TBL] [Abstract][Full Text] [Related]
9. [Testicular endocrine function in patients with prostatic cancer receiving medical castration by long-term administration of LH-RH agonists]. Isurugi K; Kondo Y; Hirasawa K; Oyamatsu T; Honma Y Nihon Hinyokika Gakkai Zasshi; 1989 Oct; 80(10):1466-73. PubMed ID: 2513445 [TBL] [Abstract][Full Text] [Related]
10. The treatment of prostatic cancer by LH-RH agonist. Imai K; Yamanaka H; Yuasa H; Yoshida M; Asano M; Kaetsu I Prog Clin Biol Res; 1987; 243A():429-34. PubMed ID: 3116552 [No Abstract] [Full Text] [Related]
11. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer. Schally AV; Redding TW Proc Natl Acad Sci U S A; 1987 Oct; 84(20):7275-9. PubMed ID: 2890164 [TBL] [Abstract][Full Text] [Related]
12. Concurrent thymoma and lymphoma: a report of two cases. Skinnider LF; Alexander S; Horsman D Hum Pathol; 1982 Feb; 13(2):163-6. PubMed ID: 7042524 [TBL] [Abstract][Full Text] [Related]
13. Luteinizing hormone-releasing hormone (LH-RH) analogs in treatment of prostatic cancer. Clinical perspective. Smith JA Urology; 1986 Jan; 27(1 Suppl):9-15. PubMed ID: 3079936 [TBL] [Abstract][Full Text] [Related]
14. Treatment of metastatic carcinoma of the prostate with leuprolide, an LHRH analogue. Smith JA Prog Clin Biol Res; 1985; 185A():279-85. PubMed ID: 3929267 [No Abstract] [Full Text] [Related]
15. Case of primary thymic papillary adenocarcinoma associated with type AB thymoma and thymic cysts. Kitamura M; Okada H; Miyahara S; Matsunaga A; Kadomatsu Y; Itagaki S; Kiriu T Pathol Int; 2020 Jun; 70(6):370-372. PubMed ID: 32180299 [No Abstract] [Full Text] [Related]
16. Leuprolide: a review of its effects in animals and man. Drago JR; Rohner T; Santen R; Manni A; Lipton A; Harvey H; English H Br J Clin Pract Suppl; 1985 Mar; 37():4-7, 16-9. PubMed ID: 3931664 [No Abstract] [Full Text] [Related]
17. Gonadotropin releasing hormone analogue antiandrogen failure secondary to a pituitary adenoma. Ogan K; Berger M; Ball R J Urol; 1998 Aug; 160(2):497-8. PubMed ID: 9679910 [No Abstract] [Full Text] [Related]
18. Newer methods of hormonal therapy for prostate cancer. Soloway MS Urology; 1984 Nov; 24(5 Suppl):30-8. PubMed ID: 6437034 [TBL] [Abstract][Full Text] [Related]
19. Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate. Smith JA; Glode LM; Wettlaufer JN; Stein BS; Glass AG; Max DT; Anbar D; Jagst CL; Murphy GP Urology; 1985 Feb; 25(2):106-14. PubMed ID: 3918369 [TBL] [Abstract][Full Text] [Related]
20. Comparison of leuprolide and diethylstilbestrol for stage D2 adenocarcinoma of prostate. Sharifi R; Lee M; Ojeda L; Ray P; Stobnicki M; Guinan P Urology; 1985 Aug; 26(2):117-24. PubMed ID: 3927551 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]